BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00523328

Enrollment

Registered

2007-08-31

Start date

2007-08-31

Completion date

2008-10-31

Last updated

2016-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, Arthritis, BG9924, methotrexate

Brief summary

This study is to observe the long-term treatment of BG9924

Detailed description

Extension study for 104RA203 (NCT 00458861)

Interventions

DRUGBG9924

dosage administered as per Biogen-idec protocol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Must be a participant from Study 104RA203 (NCT 00458861)

Exclusion criteria

* Participants with a significant change in medical history from their previous BG9924 Study 104RA203 (NCT 00458861). * Nursing mothers, pregnant women, or women who are planning to become pregnant while in the study. * Male and female participants of child-bearing potential not willing to practice effective birth control for the duration of the study. NOTE: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame
To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.	The duration of this study is 18 months.

Countries

Belgium, Canada, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026